Rodney Sinclair
Overview
Explore the profile of Rodney Sinclair including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
220
Citations
2684
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Thomas M, Sinclair R
Australas J Dermatol
. 2024 Dec;
66(1):40-41.
PMID: 39620606
No abstract available.
12.
Akiska Y, Mirmirani P, Roseborough I, Mathes E, Bhutani T, Ambrosy A, et al.
JAMA Dermatol
. 2024 Nov;
161(1):87-95.
PMID: 39565602
Importance: The results of small studies suggest that off-label use of low-dose oral minoxidil (LDOM) may be safe and effective for patients with hair loss, but larger trials and standardized...
13.
Thomas M, Paranjape M, Sinclair R
Clin Exp Dermatol
. 2024 Nov;
PMID: 39545490
No abstract available.
14.
Sinclair R, Mesinkovska N, Mitra D, Wajsbrot D, Law E, Wolk R, et al.
Am J Clin Dermatol
. 2024 Oct;
26(1):109-119.
PMID: 39441519
Background: The ALLEGRO phase 2b/3 study investigated the efficacy and safety of ritlecitinib in patients with alopecia areata (AA). Objective: To describe the impact of ritlecitinib on patient-reported hair loss...
15.
Piliang M, Lynde C, King B, Mirmirani P, Sinclair R, Senna M, et al.
J Am Acad Dermatol
. 2024 Oct;
92(2):276-284.
PMID: 39423930
Background: Few treatments for alopecia areata have demonstrated sustained efficacy. Objective: Evaluate the efficacy and safety of continued ritlecitinib treatment to week 48 in patients with alopecia areata with or...
16.
Mesinkovska N, King B, Zhang X, Guttman-Yassky E, Magnolo N, Sinclair R, et al.
J Dermatol
. 2024 Sep;
51(11):1414-1424.
PMID: 39328096
This post-hoc analysis of the ALLEGRO phase 2b/3 study (NCT03732807) evaluated the efficacy and safety of ritlecitinib, an oral Janus kinase 3/TEC family kinase inhibitor, in patients with alopecia totalis...
17.
Darchini-Maragheh E, Moussa A, Wall D, Meah N, Sinclair R
J Eur Acad Dermatol Venereol
. 2024 Sep;
PMID: 39291903
No abstract available.
18.
Darchini-Maragheh E, Moussa A, Rees H, Jones L, Bokhari L, Sinclair R
Clin Exp Dermatol
. 2024 Aug;
50(2):267-278.
PMID: 39110905
Background: Clinician-reported outcome measures (ClinROMs) are an important part of disease assessment in daily practice and clinical trials. There is a broad disagreement on the most appropriate ClinROM for a...
19.
Beyzaee A, Babaei M, Ghoreishi B, Waskiel-Burnat A, Rudnicka L, Starace M, et al.
Int J Dermatol
. 2024 Jul;
63(12):1685-1690.
PMID: 38991994
Frontal fibrosing alopecia (FFA) is a primary cicatricial alopecia characterized by hairline recession, pruritus, and facial papules (FP). Various therapies are used to stabilize disease activity and induce remission. However,...
20.
Sinclair R, Law E, Zhang X, Zhang F, Napatalung L, Zwillich S, et al.
Dermatology
. 2024 Jun;
240(5-6):767-777.
PMID: 38934147
Introduction: Patients with alopecia areata (AA) report high levels of dissatisfaction with commonly used treatments. Patient-reported outcomes are essential to understanding patients' experiences with AA treatments. The objective of this...